Earnings Feed
Start Free
Home/Filings/4/0000947871-25-000898
4//SEC Filing

ORBIMED ADVISORS LLC 4

Accession 0000947871-25-000898

CIK 0001720580other
View on SEC.govCompany Profile

Filed

Oct 9, 8:00 PM ET

Accepted

Oct 10, 8:06 PM ET

Size

26.3 KB

Accession

0000947871-25-000898

Insider Transaction Report

Form 4
Period: 2025-10-08
Adicet Bio, Inc.ACET
ORBIMED ADVISORS LLC
10% Owner
Transactions
  • Purchase

    Common Stock

    2025-10-08$1.00/sh+1,500,000$1,500,000→ 9,026,359 total(indirect: See footnotes)
  • Purchase

    Common Stock

    2025-10-08$1.00/sh+3,500,000$3,500,000→ 4,490,254 total(indirect: See footnotes)
Holdings

  • Common Stock

    (indirect: See footnotes)
    646,657

  • Common Stock

    (indirect: See footnotes)
    1,027,885

  • Common Stock

    (indirect: See footnotes)
    1,255,985
OrbiMed Capital GP V LLC
10% Owner
Transactions
  • Purchase

    Common Stock

    2025-10-08$1.00/sh+3,500,000$3,500,000→ 4,490,254 total(indirect: See footnotes)
  • Purchase

    Common Stock

    2025-10-08$1.00/sh+1,500,000$1,500,000→ 9,026,359 total(indirect: See footnotes)
Holdings

  • Common Stock

    (indirect: See footnotes)
    646,657

  • Common Stock

    (indirect: See footnotes)
    1,255,985

  • Common Stock

    (indirect: See footnotes)
    1,027,885
OrbiMed Israel GP Ltd.
10% Owner
Transactions
  • Purchase

    Common Stock

    2025-10-08$1.00/sh+1,500,000$1,500,000→ 9,026,359 total(indirect: See footnotes)
  • Purchase

    Common Stock

    2025-10-08$1.00/sh+3,500,000$3,500,000→ 4,490,254 total(indirect: See footnotes)
Holdings

  • Common Stock

    (indirect: See footnotes)
    646,657

  • Common Stock

    (indirect: See footnotes)
    1,255,985

  • Common Stock

    (indirect: See footnotes)
    1,027,885
OrbiMed Israel BioFund GP Limited Partnership
10% Owner
Transactions
  • Purchase

    Common Stock

    2025-10-08$1.00/sh+3,500,000$3,500,000→ 4,490,254 total(indirect: See footnotes)
  • Purchase

    Common Stock

    2025-10-08$1.00/sh+1,500,000$1,500,000→ 9,026,359 total(indirect: See footnotes)
Holdings

  • Common Stock

    (indirect: See footnotes)
    1,255,985

  • Common Stock

    (indirect: See footnotes)
    1,027,885

  • Common Stock

    (indirect: See footnotes)
    646,657
OrbiMed Capital GP VI LLC
10% Owner
Transactions
  • Purchase

    Common Stock

    2025-10-08$1.00/sh+3,500,000$3,500,000→ 4,490,254 total(indirect: See footnotes)
  • Purchase

    Common Stock

    2025-10-08$1.00/sh+1,500,000$1,500,000→ 9,026,359 total(indirect: See footnotes)
Holdings

  • Common Stock

    (indirect: See footnotes)
    1,255,985

  • Common Stock

    (indirect: See footnotes)
    646,657

  • Common Stock

    (indirect: See footnotes)
    1,027,885
OrbiMed Genesis GP LLC
10% Owner
Transactions
  • Purchase

    Common Stock

    2025-10-08$1.00/sh+1,500,000$1,500,000→ 9,026,359 total(indirect: See footnotes)
  • Purchase

    Common Stock

    2025-10-08$1.00/sh+3,500,000$3,500,000→ 4,490,254 total(indirect: See footnotes)
Holdings

  • Common Stock

    (indirect: See footnotes)
    1,255,985

  • Common Stock

    (indirect: See footnotes)
    646,657

  • Common Stock

    (indirect: See footnotes)
    1,027,885
OrbiMed Israel GP II, L.P.
10% Owner
Transactions
  • Purchase

    Common Stock

    2025-10-08$1.00/sh+1,500,000$1,500,000→ 9,026,359 total(indirect: See footnotes)
  • Purchase

    Common Stock

    2025-10-08$1.00/sh+3,500,000$3,500,000→ 4,490,254 total(indirect: See footnotes)
Holdings

  • Common Stock

    (indirect: See footnotes)
    646,657

  • Common Stock

    (indirect: See footnotes)
    1,255,985

  • Common Stock

    (indirect: See footnotes)
    1,027,885
OrbiMed Advisors Israel II Ltd
10% Owner
Transactions
  • Purchase

    Common Stock

    2025-10-08$1.00/sh+3,500,000$3,500,000→ 4,490,254 total(indirect: See footnotes)
  • Purchase

    Common Stock

    2025-10-08$1.00/sh+1,500,000$1,500,000→ 9,026,359 total(indirect: See footnotes)
Holdings

  • Common Stock

    (indirect: See footnotes)
    646,657

  • Common Stock

    (indirect: See footnotes)
    1,027,885

  • Common Stock

    (indirect: See footnotes)
    1,255,985
Footnotes (7)
  • [F1]These securities were purchased in an underwritten registered direct offering.
  • [F2]These securities are held of record by OrbiMed Israel Partners Limited Partnership ("OIP"). OrbiMed Israel BioFund GP Limited Partnership ("OrbiMed BioFund") is the general partner of OIP, and OrbiMed Israel GP Ltd. ("OrbiMed Israel GP") is the general partner of OrbiMed BioFund. By virtue of such relationships, OrbiMed BioFund and OrbiMed Israel GP may be deemed to have voting and investment power over the shares of common stock held by OIP and, as a result, may be deemed to have beneficial ownership over such shares of common stock. OrbiMed Israel GP exercises this investment and voting power through an investment committee comprised of Carl L. Gordon and Erez Chimovits, each of whom disclaims beneficial ownership over the shares of common stock held by OIP.
  • [F3]These securities are held of record by OrbiMed Israel Partners II, L.P. ("OIP II"). OrbiMed Israel GP II, L.P. ("OrbiMed Israel GP II") is the general partner of OIP II, and OrbiMed Advisors Israel II Limited ("OrbiMed Israel II") is the general partner of OrbiMed Israel GP II. By virtue of such relationships, OrbiMed Israel GP II and OrbiMed Israel II may be deemed to have voting and investment power over the shares of common stock held by OIP II and, as a result, may be deemed to have beneficial ownership over such shares of common stock. OrbiMed Israel II exercises this investment and voting power through an investment committee comprised of Carl L. Gordon, David Bonita, and Erez Chimovits, each of whom disclaims beneficial ownership over the shares of common stock held by OIP II.
  • [F4]These securities are held of record by OrbiMed Private Investments V, LP ("OPI V"). OrbiMed Capital GP V LLC ("GP V") is the general partner of OPI V, and OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power over the shares of common stock held by OPI V and, as a result, may be deemed to have beneficial ownership over such shares of common stock. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership over the shares of common stock held by OPI V.
  • [F5]These securities are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the general partner of OPI VI, and OrbiMed Advisors is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting and investment power over the shares of common stock held by OPI VI and, as a result, may be deemed to have beneficial ownership over such shares of common stock. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership over the shares of common stock held by OPI VI.
  • [F6]These securities are held of record by OrbiMed Genesis Master Fund, L.P. ("Genesis"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of Genesis, and OrbiMed Advisors is the managing member of Genesis. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting and investment power over the shares of common stock held by Genesis and, as a result, may be deemed to have beneficial ownership over such shares of common stock. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership over the shares of common stock held by Genesis.
  • [F7]Each of OrbiMed Advisors, OrbiMed BioFund, OrbiMed Israel GP, OrbiMed Israel GP II, OrbiMed Israel II, GP V, GP VI, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

Documents

1 file

Issuer

Adicet Bio, Inc.

CIK 0001720580

→
Entity typeother
IncorporatedDE

Related Parties

1
  • filerCIK 0001055951

Filing Metadata

Form type
4
Filed
Oct 9, 8:00 PM ET
Accepted
Oct 10, 8:06 PM ET
Size
26.3 KB
View on SEC.gov